Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 366

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 366
---
Income taxes ( 98) ( 2,076) ( 2,272)
Net profit/loss (-) € 75,364 215,685 ( 146,570)
Basic and diluted earnings/loss (-) per share from discontinued operations € 1.14 3.27 ( 2.23)
Weighted average number of shares (in thousands of shares) 65,897 65,884 65,699
Weighted average number of shares - Diluted (in thousands of shares) 65,942 65,933 65,699
Jyseleca® product net sales in Europe amounted to€ 11.5 million in 2024, compared to €112.3 million in 2023 and €87.6 million in 2022, of which €0.7 million realized in Belgium (€8.1 million in 2023 and €7.3 million in 2022). BeginningFebruary 1, 2024, all economics linked to the sales of Jyseleca® in Europe are for the benefit of Alfasigma.
Collaboration revenues in discontinued operations related to revenue recognition of the collaboration agreement with Gilead for the filgotinib development amount to €26.0 million in 2024 compared to€ 429.4 million in 2023 and €174.4 million in 2022. The sale of the Jyseleca® business to Alfasigma on January 31, 2024 led to the full recognition in revenue in 2024 of the remaining deferred income related to filgotinib.
We refer to note 2 “ Summary of significant transactions” for a general description of our collaboration with Gilead.
All filgotinib development expenses and all remaining G& A andS& M expenses relating to Jyseleca® are recharged to Alfasigma, which explains the decrease in those expenses.
Other operating income includes€52.5 million related to the gain on the sale of the Jyseleca® business to Alfasigma in 2024.

F-33

Table of Contents

III Cash flow used in discontinued operations

                                                     2024                                                          
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                     (Euro,                                                        
  Net cash flow used in operating activities         €                  ( 36,367)      ( 175,627)      ( 191,095